BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 37156483)

  • 21. Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123.
    Zanotta S; Galati D; De Filippi R; Pinto A
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm.
    Economides MP; McCue D; Lane AA; Pemmaraju N
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):941-946. PubMed ID: 31465247
    [No Abstract]   [Full Text] [Related]  

  • 23. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy.
    Riaz W; Zhang L; Horna P; Sokol L
    Cancer Control; 2014 Oct; 21(4):279-89. PubMed ID: 25310209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasmacytoid dendritic cell neoplasms.
    Lee YJ; Kim Y; Park SH; Jo JC
    Blood Res; 2023 Apr; 58(S1):90-95. PubMed ID: 37105563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expanding the Immunophenotypic Spectrum of Neoplastic and Reactive Plasmacytoid Dendritic Cells.
    Wu SJ; Sadigh S; Lane AA; Pinkus GS
    Am J Clin Pathol; 2023 May; 159(5):455-463. PubMed ID: 36880313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With a Bcl-2 Inhibitor.
    Egger A; Coello D; Kirsner RS; Brehm JE
    J Drugs Dermatol; 2021 May; 20(5):550-551. PubMed ID: 33938687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A blastic plasmacytoid dendritic cell neoplasm-like immunophenotype is negatively associated with CEBPA bZIP mutation and predicts unfavorable prognosis in acute myeloid leukemia.
    Song J; Li W; Bai Y; Zhou P; Niu J; Niu X; Liu Y; Liu X; Drokow EK; Sun K; Zhou H
    Ann Hematol; 2024 Feb; 103(2):463-473. PubMed ID: 38183444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
    Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S
    J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The advances in therapy of blastic plasmacytoid dendritic cell neoplasm.
    Kerr D; Sokol L
    Expert Opin Investig Drugs; 2018 Sep; 27(9):733-739. PubMed ID: 30118336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
    Pemmaraju N; Kantarjian H; Sweet K; Wang E; Senapati J; Wilson NR; Konopleva M; Frankel AE; Gupta V; Mesa R; Ulrickson M; Gorak E; Bhatia S; Budak-Alpdogan T; Mason J; Garcia-Romero MT; Lopez-Santiago N; Cesarman-Maus G; Vachhani P; Lee S; Bhatt VR; Blum W; Walter RB; Bixby D; Gojo I; Duvic M; Rampal RK; de Lima M; Foran J; Fathi AT; Hall AC; Jacoby MA; Lancet J; Mannis G; Stein AS; Mims A; Rizzieri D; Olin R; Perl A; Schiller G; Shami P; Stone RM; Strickland S; Wieduwilt MJ; Daver N; Ravandi F; Vasu S; Guzman M; Roboz GJ; Khoury J; Qazilbash M; Aung PP; Cuglievan B; Madanat Y; Kharfan-Dabaja MA; Pawlowska A; Taylor J; Tallman M; Dhakal P; Lane AA
    Blood; 2023 Feb; 141(6):567-578. PubMed ID: 36399715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Hammond D; Pemmaraju N
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):565-574. PubMed ID: 32336420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis, treatment, and genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A review.
    Wang Y; Xiao L; Yin L; Zhou L; Deng Y; Deng H
    Medicine (Baltimore); 2023 Feb; 102(7):e32904. PubMed ID: 36800625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights.
    Pemmaraju N; Wilson NR; Senapati J; Economides MP; Guzman ML; Neelapu SS; Kazemimood R; Davis RE; Jain N; Khoury JD; Sugita M; Cai T; Smith J; Frattini MG; Garton A; Roboz G; Konopleva M
    Leuk Res; 2022 Oct; 121():106928. PubMed ID: 35963025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemical analysis of CD123, CD56 and CD4 for the diagnosis of minimal bone marrow involvement by blastic plasmacytoid dendritic cell neoplasm.
    Hwang K; Park CJ; Jang S; Chi HS; Huh JR; Lee JH; Suh C; Lee KH
    Histopathology; 2013 Apr; 62(5):764-70. PubMed ID: 23470050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data.
    Beziat G; Ysebaert L
    Onco Targets Ther; 2020; 13():5199-5205. PubMed ID: 32606740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases.
    Sun W; Liu H; Kim Y; Karras N; Pawlowska A; Toomey D; Kyono W; Gaynon P; Rosenthal J; Stein A
    J Hematol Oncol; 2018 May; 11(1):61. PubMed ID: 29720227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expression.
    Tang H; Panse G; Braddock D; Perincheri S; Xu ML; McNiff JM
    J Cutan Pathol; 2023 Jul; 50(7):595-600. PubMed ID: 37082914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN).
    Alfayez M; Konopleva M; Pemmaraju N
    Expert Opin Biol Ther; 2020 Feb; 20(2):115-123. PubMed ID: 31801379
    [No Abstract]   [Full Text] [Related]  

  • 39. Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023.
    Pemmaraju N; Kantarjian H
    Clin Adv Hematol Oncol; 2023 May; 21(5):257-264. PubMed ID: 37145496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Jen EY; Gao X; Li L; Zhuang L; Simpson NE; Aryal B; Wang R; Przepiorka D; Shen YL; Leong R; Liu C; Sheth CM; Bowen S; Goldberg KB; Farrell AT; Blumenthal GM; Pazdur R
    Clin Cancer Res; 2020 Feb; 26(3):532-536. PubMed ID: 31548341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.